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Role of large-conductance Ca2+-activated K+
channels in adenosine A1 receptor-mediated
pharmacological postconditioning in H9c2 cells
Laurice Fretwell and John M. Dickenson
Abstract: Ischaemic postconditioning is a phenomenon whereby short periods of ischaemia applied during the start of re-
perfusion protect the myocardium from the damaging consequences of reperfusion. As such, pharmacological-induced
postconditioning represents an attractive therapeutic strategy for reducing reperfusion injury during cardiac surgery and fol-
lowing myocardial infarction. The primary aim of this study was to determine the role of large-conductance Ca2+-activated
potassium channels (BKCa channels) in adenosine A1 receptor-induced pharmacological postconditioning in the rat embry-
onic cardiomyoblast-derived cell line H9c2. H9c2 cells were exposed to 6 h hypoxia (0.5% O2) followed by 18 h reoxyge-
nation (H/R) after which cell viability was assessed by monitoring lactate dehydrogenase (LDH) release and caspase-3
activation. The adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA; 100 nmol/L) or the BKCa channel opener
NS1619 (10 mmol/L) were added for 30 min at the start of reoxygenation following 6 h hypoxic exposure. Where appro-
priate, cells were treated (15 min) before pharmacological postconditioning with the BKCa channel blockers paxilline
(1 mmol/L) or iberiotoxin (100 nmol/L). Pharmacological postconditioning with CPA or NS1619 significantly reduced
H/R-induced LDH release. Treatment with paxilline or iberiotoxin attenuated adenosine A1 receptor and NS1619-induced
pharmacological postconditioning. These results have shown for the first time that BKCa channels are involved in adeno-
sine A1 receptor-induced pharmacological postconditioning in a cell model system.
Key words: adenosine, H9c2 cells, large-conductance Ca2+-activated potassium channel, hypoxia, adenosine A1 receptor,
pharmacological postconditioning.
Résumé : Le postconditionnement ischémique est un phénomène par lequel de brèves périodes d’ischémie appliquées au
début de la reperfusion protègent le myocarde contre les effets préjudiciables de la reperfusion. En tant que tel, le postcon-
ditionnement induit de manière pharmacologique représente une stratégie thérapeutique attrayante pour diminuer la lésion
de reperfusion durant une intervention cardiaque et après un infarctus du myocarde. La présente étude a eu comme princi-
pal objectif de déterminer le rôle des canaux potassiques de grande conductance activés par le Ca2+ (canaux BKCa) dans le
postconditionnement pharmacologique induit par les récepteurs A1 de l’adénosine dans la lignée de cellules H9c2 dérivée
de cardiomyoblastes embryonnaires de rats. On a exposé les cellules H9c2 à 6 h d’hypoxie (0,5 % O2), puis à 18 h de réo-
xygénation (H/R) ; on a ensuite évalué la viabilité cellulaire en examinant la libération de la lactate déshydrogénase
(LDH) et l’activation de la caspase-3. On a ajouté l’agoniste des récepteurs A1 de l’adénosine, N6-cyclopentyladénosine
(CPA ; 100 nmol/L), ou l’ouvreur de canaux BKCa, NS1619 (10 mmol/L), durant 30 min, au début de la réoxygénation qui
a suivi l’exposition hypoxique de 6 h. Les cellules appropriées ont été traitées (15 min) avant le postconditionnement
ischémique avec les bloqueurs des canaux BKCa paxilline (1 mmol/L) et ibériotoxine (100 nmol/L). Le postconditionne-
ment pharmacologique avec la CPA ou le NS1619 a réduit significativement la libération de LDH induite par l’H/R. Le
traitement avec la paxilline ou l’ibériotoxine a atténué le postconditionnement pharmacologique induit par le récepteur A1
de l’adénosine ou le NS1619. Ces résultats sont les premiers à démontrer le rôle des canaux BKCa dans le postconditionne-
ment pharmacologique induit pat les récepteurs A1 de l’adénosine dans un modèle cellulaire.
Mots-clés : adénosine, cellules H9c2, canal potassique de grande conductance activé par le Ca2+, hypoxie, récepteur A1 de
l’adénosine, postconditionnement pharmacologique.
[Traduit par la Rédaction]
Introduction
Ischaemic preconditioning is a well-characterized phe-
nomenon in which brief periods of ischaemia can protect
the myocardium from infarction induced by a subsequent
and prolonged ischaemic attack (Murry et al. 1986). More
recently, Zhao et al. (2003) reported another form of cardio-
protection, termed ischaemic postconditioning, which in-
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volves short periods of ischaemia applied during the start of
reperfusion after a prolonged ischaemic insult. From a
clinical viewpoint, ischaemic postconditioning represents an
attractive therapeutic approach for reducing reperfusion-
induced myocardial injury.
The molecular mechanisms underlying ischaemic precon-
ditioning have been extensively studied, resulting in a num-
ber of membrane-bound receptors, predominantly belonging
to the G protein-coupled receptor (GPCR) superfamily,
being implicated in cardioprotection including adenosine A1
and A3 receptors (Sommerschild and Kirkebøen 2000; Head-
rick et al. 2003; Peart and Headrick 2007). The cardiopro-
tective effects of ischaemic preconditioning can be
mimicked either by direct stimulation of the above-
mentioned receptors or via activation of the signal trans-
duction pathways involved, using selective pharmacological
agents (pharmacological preconditioning). Many of the re-
ceptors and key signalling pathways associated with ischae-
mic preconditioning are also involved in cardioprotection
induced by ischaemic postconditioning (Burley and Baxter
2009).
The cardioprotective signal transduction mechanisms trig-
gered by the adenosine A1 receptor have been widely
studied and include the activation of several protein kinases,
including protein kinase C, extracellular signal-regulated
kinase 1/2 (ERK1/2), and p38 MAPK (Henry et al. 1996;
Dana et al. 2000; Germack and Dickenson 2005). These
pathways enhance cell survival and modulate mitochondrial
function in part through the opening of mitochondrial ATP-
sensitive potassium channels (mKATP channels) located on
the inner mitochondrial membrane (Liang 1996) and inhibi-
tion of the mitochondrial permeability transition pore (Ju-
haszova et al. 2004).
Large-conductance Ca2+-activated potassium channels
(BKCa channels), which are abundantly expressed on the
plasma membrane of vascular smooth muscle cells (Ko et
al. 2008), have recently been implicated in cardioprotection
against ischaemia and reperfusion injury in isolated perfused
guinea-pig heart (Xu et al. 2002). However, evidence to date
suggests that in cardiac myocytes BKCa channels are ex-
pressed only on the inner mitochondrial membrane and not
at the cell surface (Xu et al. 2002; Wang et al. 2008). Since
the observation by Xu et al. (2002), BKCa channels have
been implicated in ischaemic preconditioning against ischae-
mia and reperfusion injury in isolated rat and mouse hearts,
anaesthetized dogs, and isolated cardiac myocytes (Shintani
et al. 2004; Wang et al. 2004; Cao et al. 2005a; Sato et al.
2005).
In studies using the rat embryonic cardiomyoblast-derived
cell line H9c2, we recently showed that BKCa channels are
involved in adenosine A1 receptor-induced pharmacological
preconditioning (Fretwell and Dickenson 2009). These cells,
derived from embryonic rat heart tissue (Kimes and Brandt
1976), are increasingly used as an in vitro model for studies
exploring cardioprotection, since they display similar mor-
phological, electrophysiological, and biochemical properties
to primary cardiac myocytes (Hescheler et al. 1991). There-
fore, the primary aim of this study was to determine the role
of BKCa channels in adenosine A1 receptor-induced pharma-
cological postconditioning in H9c2 cells. The results ob-
tained indicate that adenosine A1 receptor activation triggers




CPA (N6-cyclopentyladenosine), DPCPX (1,3-dipropylcy-
clopentylxanthine), and NS1619 (1,3-dihydro-1-[2-hydroxy-
5-(trifluoromethyl)phenyl]-5-trifluoromethyl-2Hbenzinor-
binaltorphimine) were obtained from Sigma Chemical Co.
(Poole, Dorset, UK). Paxilline and iberiotoxin were from
Tocris (Bristol, UK). Dulbecco’s modified Eagle’s medium
(DMEM), foetal calf serum, trypsin (10x), L-glutamine
(200 mmol/L), penicillin (10 000 U/mL) / streptomycin
(10 000 mg/mL) were purchased from BioWhittaker UK
Ltd (Berkshire, UK). All other chemicals were of analyti-
cal grade. Stock concentrations of CPA (10 mmol/L),
DPCPX (10 mmol/L), and NS1619 (10 mmol/L) were dis-
solved in DMSO. The final concentration of DMSO
was ‡0.1%.
Cell culture
Rat embryonic cardiomyoblast-derived H9c2 cells were
obtained from the European Collection of Animal Cell Cul-
tures (Porton Down, Salisbury, UK). Cells were cultured in
DMEM supplemented with 2 mmol/L L-glutamine, 10% (v/
v) foetal calf serum, and penicillin (100 U/mL) / streptomy-
cin (100 mg/mL). Cells were maintained in a humidified in-
cubator (95% air / 5% CO2) at 37 8C until 70%–80%
confluent and subcultured (1:5 split ratio) using 0.05% tryp-
sin (w/v) / 0.02% EDTA (w/v).
Experimental protocol
H9c2 cells in glucose-free and serum-free DMEM were
exposed to 6 h hypoxia using a hypoxic incubator (5%
CO2 / 0.5% O2) at 37 8C, where O2 was replaced by N2.
Following hypoxic exposure, cells were reoxygenated in
DMEM containing 1% foetal calf serum for 18 h in a hu-
midified atmosphere (5% CO2 / 95% air) at 37 8C. For phar-
macological postconditioning, cells were exposed to the
adenosine A1 receptor agonist CPA (100 nmol/L) or the
BKCa channel opener NS1619 (10 mmol/L) for 30 min at
the start of reoxygenation following hypoxia exposure.
Where appropriate, cells were treated for 15 min with the
BKCa channel blockers paxilline (1 mmol/L) or iberiotoxin
(100 nmol/L) before the addition of CPA or NS1619. After
the above treatments, the medium containing agonists, open-
ers, and inhibitors was removed and replaced with fresh
DMEM containing 1% (v/v) foetal calf serum for the re-
mainder of the reoxygenation period.
Cell viability
H9c2 cells were plated in 96-well flat-bottomed plates at
a final density of 5000 cells/well and cultured for 24 h in
fully supplemented DMEM, after which the medium was re-
placed with glucose- and serum-free DMEM containing
2 mmol/L L-glutamine and penicillin/streptomycin (100 U/
mL). Cell viability assays were performed by determining
the activity of lactate dehydrogenase (LDH) released into
the media and detected colourimetrically (CytoTox 96 Non-
Radioactive Cytotoxicity LDH assay, Promega, Southamp-
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ton, UK). Assays were performed according to the manufac-
turer’s instructions.
Caspase 3 activity
H9c2 cells were cultured in 60 mm tissue culture dishes,
and caspase-3 activity was measured following 6 h hypoxia
using a fluorescence-based assay. Cells were harvested using
0.05% trypsin (w/v) / 0.02% EDTA (w/v), centrifuged
(1000g for 5 min), and the resulting cell pellets resuspended
in 120 mL lysis buffer (25 mmol/L HEPES, 2.5 mmol/L
CHAPS, 2.5 mmol/L DDT, pH 7.4) and incubated on ice
for 20 min. Cell lysates were centrifuged (14 000g at 4 8C)
and the supernatant collected and stored on ice. Aliquots of
supernatant (30 mL) were transferred to black 96-well micro-
plates (Greiner Bio-One, Stonehouse, Gloucestershire, UK)
and 50 mL assay buffer (20 mmol/L HEPES, 5 mmol/L
DDT, 0.1% CHAPS, 2 mmol/L EDTA, pH 7.4) and 20 mL
caspase-3 substrate (0.5 mmol/L; acetyl-DEVD-7-amido-
methylcoumarin) were added. Fluorescence readings (lex =
355 nm and lem = 460 nm) were taken over a 2 h period.
Protein level was determined using the Bio-Rad DC Protein
assay kit (Bio-Rad Laboratories, Hertfordshire, UK) and
caspase-3 activity per min per mg protein determined and
expressed as a percentage of basal activity.
Data analysis
Statistical significance was determined by ANOVA with a
post hoc Tukey’s test (p < 0.05 was considered statistically
significant). All data are presented as means ± SEM. The n
in the text refers to the number of separate experiments.
Results
Hypoxia/reoxygenation-induced cell death in H9c2 cells
Cell-based systems using hypoxia/reoxygenation protocols
are widely used as an in vitro model of ischaemia/reperfusion
injury. In this study, H9c2 cells were exposed to 6 h hypo-
xia (0.5% O2) in serum-free and glucose-free medium, fol-
lowed by 18 h reoxygenation in medium containing
glucose and 1% serum, as described previously (Germack
and Dickenson 2005). The effects of hypoxia and reoxyge-
nation on cell viability were assessed by monitoring LDH
activity released into the medium and caspase-3 activity.
As shown in Fig. 1, 6 h hypoxia followed by 18 h reoxy-
genation (H/R) induced a marked increase in LDH release
compared with cells exposed to 6 h hypoxia. In marked
contrast, there was no measurable increase in caspase-3 ac-
tivity following H/R, suggesting that apoptosis had not oc-
curred.
Role of BKCa channels in NS1619-induced
postconditioning in H9c2 cells
The ability of BKCa channel activation to trigger postcon-
ditioning was assessed by treating H9c2 cells during the first
30 min of reoxygenation with the BKCa channel opener
NS1619 (10 mmol/L). We have previously shown that this
concentration of NS1619 triggers pharmacological precondi-
tioning against 6 h hypoxia-induced cell death in H9c2 cells
(Fretwell and Dickenson 2009). As shown in Fig. 2, post-
conditioning with NS1619 significantly reversed H/R-
induced LDH release (n = 7, p < 0.001). Furthermore, the
protection afforded by NS1619 was reversed by the BKCa
channel blockers paxilline (1 mmol/L; n = 5, p < 0.05)
and iberiotoxin (10 nmol/L; n = 5, p < 0.05), confirming
the involvement of the BKCa channel (Fig. 2).
Role of BKCa channels in adenosine A1 receptor-induced
postconditioning in H9c2 cells
We recently reported that the selective adenosine A1 re-
ceptor agonist CPA triggers pharmacological precondition-
ing against 6 h hypoxia-induced cell death in H9c2 cells
(Fretwell and Dickenson 2009). In this study, pharmacologi-
cal postconditioning with CPA triggered protection against
H/R-induced LDH release (Fig. 3). CPA-mediated protection
was reversed by the adenosine A1 receptor antagonist
DPCPX (10 mmol/L; n = 6, p < 0.01), confirming the in-
volvement of the A1 receptor. Furthermore, the BKCa chan-
nel blockers paxilline (1 mmol/L; n = 6, p < 0.05) and
Fig. 1. Cell death induced by hypoxia/reoxygenation in H9c2 cells.
Cells were exposed to 6 h normoxia (control), 6 h hypoxia, or 6 h
hypoxia followed by 18 h reoxygenation, then cell death was as-
sessed by (a) lactate dehydrogenase (LDH) release or (b) caspase-3
activity. Data are expressed as percentage of the control. Each bar
represents the mean ± SEM from 6 separate experiments; for each
experiment, the mean was taken from 2 (caspase-3) or 6 (LDH) re-
plicates. *, p < 0.05 and **, p < 0.01 vs. control.
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iberiotoxin (10 nmol/L; n = 6, p < 0.05) significantly attenu-
ated the CPA-mediated response, suggesting a role for the
BKCa channel in adenosine A1 receptor-mediated postcondi-
tioning in H9c2 cells.
Discussion
We recently described a role for the BKCa channel in ad-
enosine A1 receptor-induced pharmacological precondition-
ing in H9c2 cells (Fretwell and Dickenson 2009). The
primary aim of this study was to investigate the potential
role of the BKCa channel in adenosine A1 receptor-mediated
postconditioning.
Ischaemic postconditioning is a newly described phenom-
enon that involves short intermittent periods of ischaemia
applied at the start of reperfusion, protecting the myocar-
dium from the damaging consequences of reperfusion (Zhao
et al. 2003). Since its initial discovery, ischaemic postcondi-
tioning has been observed in many animal models (Burley
and Baxter 2009) and, importantly, in the human heart
(Staat et al. 2005). Identifying the molecular mechanisms
that trigger postconditioning may facilitate the discovery of
suitable therapeutic targets for clinical use against reperfu-
sion injury, either during surgical procedures or following
acute myocardial infarction. Indeed, many of the receptors
and key signalling pathways traditionally associated with is-
chaemic preconditioning are also involved in cardioprotec-
tion induced by ischaemic postconditioning (Burley and
Baxter 2009).
The roles of the adenosine A1 receptor in ischaemic pre-
conditioning and associated signal transduction pathways
have been extensively studied in many model systems (Som-
merschild and Kirkebøen 2000; Headrick et al. 2003; Peart
and Headrick 2007). However, the involvement of the ad-
enosine A1 receptor in ischaemic postconditioning is not
clear-cut (Burley and Baxter 2009). Xi et al. (2008) reported
that the infarct limiting protection of ischaemic postcondi-
tioning was absent in adenosine A1 receptor knockout mice.
Similarly, the ischaemic postconditioning in normal and hy-
percholesterolemic rabbits was abolished by the adenosine
A1 receptor antagonist DPCPX (Donato et al. 2007). Studies
using isolated rat ventricular myocytes have also demon-
strated that pharmacological postconditioning with adeno-
sine is blocked by DPCPX (Lu et al. 2006). In marked
contrast, several studies suggest that the adenosine A1 recep-
tor is not involved in ischaemic postconditioning (Kin et al.
2005; Philipp et al. 2006). The reasons for these differences
may reflect differences in experimental protocol and model
systems used. However, the data presented in this study, us-
ing the rat embryonic cardiomyoblast-derived cell line H9c2,
support the role of the adenosine A1 receptor in triggering
postconditioning.
Although a number of studies have implicated a role of
the mitochondrial BKCa channel in both ischaemic and phar-
macological preconditioning (Xu et al. 2002; Shintani et al.
2004; Wang et al. 2004; Cao et al. 2005a; Sato et al. 2005),
there are no reports to date detailing its role in postcondi-
tioning. In this study, we have shown that opening of the
BKCa channel during the onset of reoxygenation (achieved
using NS1619) attenuates H/R-induced cell injury. Impor-
tantly, paxilline and iberiotoxin inhibited the ability of
Fig. 2. The role of large-conductance Ca2+-activated potassium
channels (BKCa channels) in 1,3-dihydro-1-[2-hydroxy-5-(trifluoro-
methyl)phenyl]-5-trifluoromethyl-2Hbenzinor-binaltorphimine
(NS1619)-mediated postconditioning in H9c2 cells. Cells were ex-
posed to 6 h hypoxia, followed by 18 h reoxygenation. For the first
45 min of reoxygenation, cells were treated with paxilline (Pax;
1 mmol/L) or iberiotoxin (IbTx; 10 nmol/L) with the addition of
NS1619 (10 mmol/L) for the final 30 min of treatment. Data are
expressed as percentage of the untreated control cells exposed to
hypoxia/reoxygenation alone (=100%). Each bar represents the
mean ± SEM of 5 separate experiments, and for each experiment
the mean was taken from 6 replicates. *, p < 0.05 vs. control; #,
p < 0.05 vs. NS1619.
Fig. 3. The role of BKCa channels in adenosine A1 receptor-
mediated postconditioning in H9c2 cells. Cells were exposed to 6 h
hypoxia, followed by 18 h reoxygenation. For the first 45 min of
reoxygenation, cells were treated with 1,3-dipropylcyclopentyl-
xanthine (DPCPX; 10 mmol/L), paxilline (Pax; 1 mmol/L), or iber-
iotoxin (IbTx; 10 nmol/L), with the addition of N6-
cyclopentyladenosine (CPA; 100 nmol/L) for the final 30 min of
treatment. Data are expressed as percentage of the untreated control
cells exposed to hypoxia/reoxygenation alone (=100%). Each bar
represents the mean ± SEM of 5 separate experiments, and for each
experiment, the mean was taken from 6 replicates. ***, p < 0.001
vs. control; # #, p < 0.01 vs. NS1619; and #, p < 0.05 vs. 1,3-dihy-
dro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-trifluoromethyl-
2Hbenzinor-binaltorphimine (NS1619).
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NS1619 to block H/R-induced cell death, confirming for the
first time a role for the BKCa channel in postconditioning.
Studies using BKCa channel blockers in conjunction with
NS1619 are important since NS1619 also mediates cytopro-
tection via BKCa channel-independent pathways (Cancherini
et al. 2007; Gáspár et al. 2008). For example, NS1619 pro-
motes nonselective permeabilization of the inner mitochon-
drial membrane to ions in isolated heart mitochondria and
BKCa channel-independent delayed preconditioning in rat
cortical neuronal cultures (Cancherini et al. 2007; Gáspár et
al. 2008). Furthermore, since evidence to date suggests that
BKCa channel expression in cardiac myocytes is restricted to
the inner mitochondrial membrane, the effects of NS1619,
iberiotoxin, and paxilline are likely to be entirely mitochon-
drial (Xu et al. 2002; Wang et al. 2008). This is in contrast
to the KATP channel that mediates cardioprotection via
plasma membrane and mitochondrial-based pathways
(Hanley and Daut 2005).
We recently reported a role for the BKCa channel in ad-
enosine A1 receptor-induced pharmacological precondition-
ing in H9c2 cells (Fretwell and Dickenson 2009). In this
study, we have shown for the first time that the BKCa chan-
nel is also involved in adenosine A1 receptor-induced post-
conditioning. However, at present, the signal transduction
pathway(s) linking adenosine A1 receptor activation with
BKCa channel opening are not known. Previous studies have
shown that BKCa channel activation via the k-opioid recep-
tor and adrenomedullin involve PKC and PKA, respectively
(Cao et al. 2005a; Nishida et al. 2008). It will be interesting
to establish whether any of the protein kinases (PKC, ERK1/
2, and p38 MAPK) associated with the cardioprotective ef-
fects of the adenosine A1 receptor trigger BKCa channel
opening.
We previously showed that BKCa channel opening attenu-
ates hypoxia-induced caspase-3 activation in H9c2 cells,
suggesting anti-apoptotic effects (Fretwell and Dickenson
2009). However, in this study, we did not observe caspase-3
activation following hypoxia/reoxygenation challenge. This
is surprising, since other studies, including work from our
laboratory using neonatal rat cardiomyocytes, have shown
caspase-3 activation following hypoxia/reoxygenation (Ger-
mack and Dickenson 2005; Kang et al. 2000). Indeed, pre-
vious studies using H9c2 cells have reported that 2 h
hypoxia followed by 16 h reoxygenation triggers caspase-3
activation and apoptotic cell death (Chiu et al. 2008). The
reason(s) for the apparent lack of caspase-3 activity in this
study is not known, but may reflect the differing period of
hypoxic exposure (6 h vs. 2 h). Alternatively, apoptotic cell
death may not contribute to cell death in H9c2 cells exposed
to 6 h hypoxia prior to 16 h reoxygenation. Detailed time-
course analysis experiments (varying hypoxia exposure
times vs. varying reoxygenation times) measuring necrotic
and apoptotic cell death may shed light on this issue.
At present, the downstream cardioprotective mechanisms
associated with mitochondrial BKCa channel opening are
not fully understood. However, several studies have indi-
cated that inhibition of mitochondrial permeability transition
pore opening is downstream of this channel (Cao et al.
2005a, 2005b; Gao et al. 2005). The recent demonstration
that a single dose of cyclosporine A given at the time of re-
perfusion to patients undergoing percutaneous coronary in-
tervention for acute myocardial infarction results in infarct
size reduction (Piot et al. 2008) is an indication of the ther-
apeutic potential of inhibiting the mitochondrial permeabil-
ity transition pore. Additional protective mechanisms
associated with BKCa channel opening include reduction in
mitochondrial Ca2+ overload (Kang et al. 2007), which
would aid mitochondrial permeability transition pore clo-
sure, and the generation of reactive oxygen species (Heinen
et al. 2007). Clearly, further studies are required to ascertain
whether postconditioning induced by the adenosine A1 re-
ceptor involves mitochondrial permeability transition pore
inhibition downstream from the BKCa channel.
In summary, we have shown for the first time that BKCa
channel opening is involved in adenosine A1 receptor-
induced postconditioning. Future experiments will endeav-
our to characterize the signalling pathways that link adeno-
sine A1 receptor activation to BKCa channel opening and to
elucidate the cardioprotective mechanisms downstream of
channel opening in this model cell system.
Acknowledgements
We thank the Nottingham Trent University for financial
support.
References
Burley, D.S., and Baxter, G.F. 2009. Pharmacological targets re-
vealed by myocardial postconditioning. Curr. Opin. Pharmacol.
9(2): 177–188. doi:10.1016/j.coph.2008.11.009. PMID:
19109069.
Cancherini, D.V., Queliconi, B.B., and Kowaltowski, A.J. 2007.
Pharmacological and physiological stimuli do not promote
Ca2+-sensitive K+ channel activity in isolated heart mitochon-
dria. Cardiovasc. Res. 73(4): 720–728. doi:10.1016/j.cardiores.
2006.11.035. PMID:17208207.
Cao, C.-M., Chen, M., and Wong, T.-M. 2005a. The KCa channel
as a trigger for the cardioprotection induced by k-opioid receptor
stimulation — its relationship with protein kinase C. Br. J. Phar-
macol. 145(7): 984–991. doi:10.1038/sj.bjp.0706268. PMID:
15912131.
Cao, C.-M., Xia, Q., Gao, Q., Chen, M., and Wong, T.-M. 2005b.
Calcium-activated potassium channel triggers cardioprotection
of ischemic preconditioning. J. Pharmacol. Exp. Ther. 312(2):
644–650. doi:10.1124/jpet.104.074476. PMID:15345753.
Chiu, P.Y., Luk, K.F., Leung, H.Y., Ng, K.M., and Ko, K.M. 2008.
Schisandrin B stereoisomers protect against hypoxia/reoxygena-
tion-induced apoptosis and inhibit associated changes in Ca2+-in-
duced mitochondrial permeability transition and mitochondrial
membrane potential in H9c2 cardiomyocytes. Life Sci. 82(21–
22): 1092–1101. doi:10.1016/j.lfs.2008.03.006. PMID:18452952.
Dana, A., Skarli, M., Papakrivopoulou, J., and Yellon, D.M. 2000.
Adenosine A1 receptor induced delayed preconditioning in rab-
bits: induction of p38 mitogen-activated protein kinase activa-
tion and Hsp27 phosphorylation via a tyrosine kinase- and
protein kinase C-dependent mechanism. Circ. Res. 86(9): 989–
997. PMID:10807872.
Donato, M., D’Annunzio, V., Berg, G., Gonzalez, G., Schreier, L.,
Morales, C., et al. 2007. Ischemic postconditioning reduces in-
farct size by activation of A1 receptors and K+ATP channels in
both normal and hypercholesterolemic rabbits. J. Cardiovasc.
Pharmacol. 49(5): 287–292. doi:10.1097/FJC.0b013e31803c55fe.
PMID:17513947.
Fretwell, L., and Dickenson, J.M. 2009. Role of large-conductance
28 Can. J. Physiol. Pharmacol. Vol. 89, 2011





































































Ca2+-activated potassium channels in adenosine A1 receptor-
mediated pharmacological preconditioning in H9c2 cells. Eur. J.
Pharmacol. 618(1–3): 37–44. doi:10.1016/j.ejphar.2009.07.008.
PMID:19619521.
Gao, Q., Zhang, S.-Z., Cao, C.-M., Bruce, I.C., and Xia, Q. 2005.
The mitochondrial permeability transition pore and the Ca2+-ac-
tivated K+ channel contribute to the cardioprotection conferred
by tumor necrosis factor-a. Cytokine, 32(5): 199–205. doi:10.
1016/j.cyto.2005.09.008. PMID:16260145.
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